Can you provide the average price target for NEUROPACE INC stock?
14 analysts have analysed NPCE and the average price target is 19.89 USD. This implies a price increase of 53% is expected in the next year compared to the current price of 13.
NASDAQ:NPCE • US6412881053
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NEUROPACE INC (NPCE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-16 | UBS | Maintains | Buy -> Buy |
| 2025-12-10 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-05-28 | HC Wainwright & Co. | Initiate | Buy |
| 2025-05-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-05-14 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-03-05 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-01-30 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-01-21 | UBS | Initiate | Buy |
| 2024-12-17 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-11-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-08-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-14 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-07-15 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-05-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-03-14 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2024-03-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-03-06 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-03-06 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-02-22 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2024-01-30 | Leerink Partners | Initiate | Outperform |
| 2023-12-27 | Lake Street | Reiterate | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 65.421M 43.72% | 79.906M 22.14% | 99.986M 25.13% | 100.92M 0.93% | 126.62M 25.47% | 161.25M 27.35% | 188.53M 16.92% | 217.68M 15.46% | |
| EBITDA YoY % growth | -27.002M 33.36% | -21.464M 20.51% | -16.1M 24.99% | -9.255M 42.52% | 7.297M 178.85% | N/A | N/A | N/A | |
| EBIT YoY % growth | -27.174M 33.38% | -21.671M 20.25% | -16.338M 24.61% | -21.383M -30.88% | -10.031M 53.09% | 4.08M 140.67% | 20.4M 400.00% | 25.5M 25.00% | |
| Operating Margin | -41.54% | -27.12% | -16.34% | -21.19% | -7.92% | 2.53% | 10.82% | 11.71% | |
| EPS YoY % growth | -1.28 33.33% | -0.95 25.78% | -0.66 30.53% | -0.77 -16.79% | -0.40 48.66% | 0.14 136.08% | 0.09 -35.71% | 0.37 300.00% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.22 -2.69% | -0.19 28.82% | -0.13 -16.57% | -0.14 -74.85% | -0.07 66.89% | -0.05 72.44% | -0.05 60.23% | -0.03 78.12% |
| Revenue Q2Q % growth | 22.319M -0.91% | 23.548M 0.12% | 27.199M -0.57% | 26.875M 1.08% | 28.387M 27.19% | 29.998M 27.39% | 33.711M 23.94% | 36.924M 37.39% |
| EBITDA Q2Q % growth | -5.53M -8.48% | -3.473M 48.32% | -520.71K 78.68% | -752.76K 50.77% | -550.8K 90.04% | -244.8K 92.95% | 357K 168.56% | 958.8K 227.37% |
| EBIT Q2Q % growth | -6.588M -28.00% | -5.044M 26.08% | -2.763M -6.28% | -3.387M -91.67% | -1.163M 82.35% | -601.8K 88.07% | -438.6K 84.13% | -71.4K 97.89% |
All data in USD
14 analysts have analysed NPCE and the average price target is 19.89 USD. This implies a price increase of 53% is expected in the next year compared to the current price of 13.
NEUROPACE INC (NPCE) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of NEUROPACE INC (NPCE) is -0.22 USD and the consensus revenue estimate is 22.32M USD.
The number of analysts covering NEUROPACE INC (NPCE) is 14.